Article
PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Oral surgery, oral medicine, oral pathology and oral radiology - 1 May 2026
Kim Dong Hyun, Koh Jiwon, Ahn Jong Seok, Moon Jimin, Kang Mingu, Park Gahee, Lim Yoojoo, Ock Chan-Young, Jeon Yoon Kyung, Jung Kyeong Cheon, Ahn Soon-Hyun, Chung Eun-Jae, Kwon Seong-Keun, Keam Bhumsuk
Abstract excerpt
OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) expression and immune phenotype (IP) are potential predictive biomarkers for immune checkpoint inhibitors (ICIs) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This study evaluated the predictive value of combining PD-L1 expression and IP in R/M HNSCC. STUDY DESIGN: Forty-one R/M HNSCC patients treated with ICI were included....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.